Equities

Notable Labs Ltd

NTBLQ:PKL

Notable Labs Ltd

Actions
  • Price (USD)0.016
  • Today's Change-0.002 / -10.61%
  • Shares traded2.47k
  • 1 Year change-99.61%
  • Beta0.8425
Data delayed at least 15 minutes, as of Nov 25 2024 20:54 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

  • Revenue in USD (TTM)313.00k
  • Net income in USD-16.74m
  • Incorporated2000
  • Employees16.00
  • Location
    Notable Labs Ltd320 Hatch DriveFOSTER CITY 94404United StatesUSA
  • Phone+1 (415) 851-2410
  • Fax+972 8993-5001
  • Websitehttps://notablelabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Molecular Pharmacology (USA) Ltd0.00-105.18k99.96k0.00---------0.0009-0.00090.00-0.01880.00-------976.60-1,219.29------------------------44.29------
Health Advance Inc-100.00bn-100.00bn122.62k3.00--0.0284----------0.0212----------------------------0.0356--100.00---21.75------
Seelos Therapeutics Inc2.01m4.09m170.02k8.000.002----0.0844156.15156.1522.91-135.500.2823--6.51134,266.7057.34-180.05---386.76----203.13-9,612.88---608.33--------48.48------
Notable Labs Ltd313.00k-16.74m172.90k16.00--0.0215--0.5524-2.47-2.470.0460.74390.0176----19,562.50-93.89-52.02-120.26-62.0937.7060.19-5,346.97-3,636.93----0.0405---52.89-11.9365.13---50.69--
Propanc Biopharma Inc0.00-1.87m236.97k1.00---------0.0372-0.03720.00-0.0060.00-------1,495.00-4,082.63---------------2.55--------35.61------
Data as of Nov 25 2024. Currency figures normalised to Notable Labs Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.89%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 30 Sep 202436.00k0.37%
Geode Capital Management LLCas of 30 Sep 202419.54k0.20%
Two Sigma Securities LLCas of 30 Sep 202415.27k0.16%
FNY Capital Management LPas of 30 Sep 202410.00k0.10%
BNP Paribas Financial Marketsas of 30 Sep 20242.20k0.02%
Group One Trading LLCas of 30 Sep 20241.27k0.01%
Morgan Stanley & Co. LLCas of 30 Sep 2024800.000.01%
Tower Research Capital LLCas of 30 Sep 2024417.000.00%
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024229.000.00%
Desjardins Securities, Inc.as of 30 Sep 2024115.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.